Immunovant Inc IMVT 深 滬
交易中 05-18 11:48:44 美东时间
26.69
-0.800
-2.91%
華盛通- 最 高27.62
- 今 開27.52
- 成交量 19.46万股
- 最 低 26.60
- 昨 收 27.49
- 總市值 543.23万
- 52周最高 30.16
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 13.79
- 委 比 50.50%
- 總股本 0.00亿
- 歷史最高 53.75
- 量 比 0.51
- 振 幅 3.71%
- 歷史最低 3.145
- 每 手 1
- 風險率 4.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant will report its financial results for Q4 and FY 2026 on May 20, 2026 at 8:00 a.m. ET. A conference call registration link and webcast details are available on the company's investor relations page. Immunovant is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases using anti-FcRn technology.
05-11 20:05
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
Earnings Call Insights: OmniAb, Inc. (OABI) Q1 2026 Management view "OmniAb delivered a very strong start to the year, largely driven by advancement of our partner programs," said President, CEO & Dir...
05-08 11:02
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
Insiders have been trading these 5 stocks: (($GLBE)), (($EYPT)), (($IMVT)), (($...
04-25 21:01
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.
04-16 01:46
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
Insiders have been trading these 5 stocks: (($IL:ESLT)), (($VOR)), (($GLBE)), (...
04-11 21:01
BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks
BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 April 2 (Reuters) - Futures tracking Wall Street's main indexe
04-02 19:36
Market-Moving News for April 2nd
GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
04-02 19:17
UPDATE 1-Immunovant's treatment for eye disease fails late-stage trials
UPDATE 1-Immunovant's treatment for eye disease fails late-stage trials Adds shares, details in paragraph 3-4 April 2 (Reuters) - Immunovant IMVT.O said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in two late-stage studies. Shares of the company were dow
04-02 17:24
Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of
04-02 17:08
